Skip navigation.

GenPhar, Inc.
http://www.genphar.com
Short Header Picture 06

news

article

For Life

For Future

Publications

2007-09-12
Complex Adenovirus-Mediated Expression of West Nile Virus C, PreM, E, and NS1 Proteins Induces both Humoral and Cellular Immune Responses
Complex Adenovirus-Mediated Expression of West Nile Virus C, PreM, E, and NS1 Proteins Induces both Humoral and Cellular Immune Responses.

Clinical and Vaccine Immunology, 2007 vol. 14 (9) pp. 1117-26
West Nile Virus (WNV), a member of the family Flaviviridae, was first identified in Africa in 1937. In recent years, it has spread into Europe and North America. The clinical manifestations of WNV infection range from mild febrile symptoms to fatal encephalitis. Two genetic lineages (lineages I and II) are recognized; lineage II is associated with mild disease, while lineage I has been associated with severe disease, including encephalitis. WNV has now spread across North America, significantly affecting both public and veterinary health. In the efforts to develop an effective vaccine against all genetic variants of WNV, we have studied the feasibility of inducing both neutralizing and cellular immune responses by de novo synthesis of WNV antigens using a complex adenoviral vaccine (CAdVax) vector. By expressing multiple WNV proteins from a single vaccine vector, we were able to induce both humoral and cellular immune responses in vaccinated mice. Neutralization assays demonstrated that the antibodies were broadly neutralizing against both lineages of WNV, with a significant preference for the homologous lineage II virus. The results from this study show that multiple antigens synthesized de novo from a CAdVax vector are capable of inducing both humoral and cellular immune responses against WNV and that a multiantigen approach may provide broad protection against multiple genetic variants of WNV.

Click here for full publication pdf
About GenPhar, Inc.

GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina.

To learn more about GenPhar and its vaccine programs, please contact us.